[Idiopathic hyperaldosteronism (IHA)].
Miyashita K, Itoh H, Nakao K.
Nihon Rinsho. 2006 May 28;Suppl 1:624-7.
Hyperaldosteronism in pregnancy.
Escher G.
Ther Adv Cardiovasc Dis. 2009 Apr;3(2):123-32. doi: 10.1177/1753944708100180. Epub 2009 Jan 26.
[Primary hyperaldosteronism].
Opocher G, Rocco S, Carpené G, Armanini D, Mantero F.
Minerva Endocrinol. 1995 Mar;20(1):49-54.
Cellular and Genetic Causes of Idiopathic Hyperaldosteronism.
Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, Anand SK, Guo Z, Stowasser M, Sasano H, Tomlins SA, Rainey WE.
Hypertension. 2018 Oct;72(4):874-880. doi: 10.1161/HYPERTENSIONAHA.118.11086.
The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
Zheng Y, Long T, Peng N, Zhen M, Ye Q, Zhang Z, He Y, Chen Z, Gan Y, Luo M, Li C, Liu Z, Guo M, Wang M, Luo X, Hu S, Liu L, Jiang T.
J Clin Endocrinol Metab. 2023 Dec 21;109(1):171-182. doi: 10.1210/clinem/dgad421.
Clinical Significance of Skeletal Fat-to-Muscle Ratio in Idiopathic Hyperaldosteronism.
Jiang Y, Li D, Cao CC, Feng W, Liu R, Xu Y, Cao C.
Clin Endocrinol (Oxf). 2025 Oct;103(4):429-435. doi: 10.1111/cen.15274. Epub 2025 May 20.
[Adrenocortical hypertension].
Kostić N, Milosević M, Jelić S, Nesović M.
Med Pregl. 2003 Jul-Aug;56(7-8):346-50. doi: 10.2298/mpns0308346k.
Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.
Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Umakoshi H, Ichijo T, Katabami T, Wada N, Ogawa Y, Yoshimoto T, Kawashima J, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Miyauchi S, Kamemura K, Fukuoka T, Yamamoto K, Otsuki M, Suzuki T, Naruse M; JPAS Study Group.
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4456-4464. doi: 10.1210/jc.2018-00866.
Clinical implications of aldosterone responsiveness to adrenocorticotropic hormone stimulation in two major subtypes of primary aldosteronism.
Watanabe D, Morimoto S, Morishima N, Ichihara A.
Clin Exp Hypertens. 2026 Dec 31;48(1):2637682. doi: 10.1080/10641963.2026.2637682. Epub 2026 Feb 27.
Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism.
Watanabe D, Morimoto S, Morishima N, Ichihara A.
Endocrine. 2024 Apr;84(1):245-252. doi: 10.1007/s12020-023-03627-w. Epub 2023 Dec 12.
